本研究基于Web of Science(WOS)数据库和CNKI(中国知网)数据库收录的兰科植物功能基因相关文献,借助CiteSpace计量工具,采用文献计量方法和知识图谱可视化技术对领域内2002-2020年间的文献进行定量统计和数据分析。在回顾近19年间国内...本研究基于Web of Science(WOS)数据库和CNKI(中国知网)数据库收录的兰科植物功能基因相关文献,借助CiteSpace计量工具,采用文献计量方法和知识图谱可视化技术对领域内2002-2020年间的文献进行定量统计和数据分析。在回顾近19年间国内外学者对兰科植物功能基因研究的探索历程及应用现状的同时,探究了该研究领域的文献发布时间、作者和国家发文量、期刊共被引分析、知识基础、关键词研究热点及主题演化的网络特征,揭示了不同时段研究热点的变化规律,并对目前该领域需解决的问题以及未来探索方向进行讨论,以期为兰科植物的进一步开发、创新和应用提供理论支撑。结果表明:(1)兰科植物功能基因研究经历了3个阶段(形成期、成长期、稳定发展期),发文量整体呈稳步增长趋势。(2)研究热点聚集于物种形成、转录组学、遗传转化、ISSR和ITS分子标记等方向;功能基因以MADS-box、ACS、MYB等基因为主,其中对参与调控花器官发育的MADS-box基因的研究最为广泛。(3)国内外形成了以Chen HW(陈虹桦)、Tsai WC(蔡文杰)、Tamura K、刘仲健、朱紫乐、崔波、孙崇波和吴建设等为主的核心作者群,但团队之间合作较为疏散。展开更多
Targeted delivery of anti-tumor drugs and overcoming drug resistance in malig-nant tumor cells remain significant clinical challenges.However,there are only few effective methods to address these issues.Extracellular ...Targeted delivery of anti-tumor drugs and overcoming drug resistance in malig-nant tumor cells remain significant clinical challenges.However,there are only few effective methods to address these issues.Extracellular vesicles(EVs),actively secreted by cells,play a crucial role in intercellular information transmis-sion and cargo transportation.Recent studies have demonstrated that engineered EVs can serve as drug delivery carriers and showed promising application prospects.Nevertheless,there is an urgent need for further improvements in the isolation and purification of EVs,surface modification techniques,drug assem-bly processes,and precise recognition of tumor cells for targeted drug delivery purposes.In this review,we summarize the applications of engineered EVs in cancer treatment and overcoming drug resistance,and current challenges asso-ciated with engineered EVs are also discussed.This review aims to provide new insights and potential directions for utilizing engineered EVs as targeted delivery systems for anti-tumor drugs and overcoming drug resistance in the near future.展开更多
Background c-Myc, EZH2 and p27 were defined to modulate anti-tumoral effects and had ability in predicting prostate cancer value of prognosis is rarely. This study aimed to investigate the patients with intermediate-r...Background c-Myc, EZH2 and p27 were defined to modulate anti-tumoral effects and had ability in predicting prostate cancer value of prognosis is rarely. This study aimed to investigate the patients with intermediate-risk prostate cancer after surgery. the behavior of prostate cancer with pro-tumoral or progression, but the research of their co-expression prognostic value of combining tri-marker together in Methods Expression levels of c-Myc, EZH2 and p27 in 129 patients with intermediate-risk prostate cancer were assessed using immunohistochemistry in a semi-quantitative manner. The expression profiles of these three markers were analyzed and investigated for association with biochemical recurrence. Results In all, fifty of 129 cases experienced biochemical recurrence during a median follow-up time of 31 months (range, 6-60 months). Of these relapse patients, one case without and 10 cases with any single positive marker were observed; 39 cases were detected with any two or all three positive markers (22 cases with any two and 17 cases with all three positive markers). Survival analysis showed that patients with over-expression of c-Myc or EZH2, and lower expression of p27 manifested significantly higher biochemical recurrence rates. Subsequent multivariate analysis revealed that c-Myc, EZH2 and p27 expression statuses showed potential in predicting relapse, respectively. Notably, combining three markers together as a "composite index" (0 or 1, vs. 2 or 3 positive markers) provided powerful prognostic value (HR 6.57, 95% CI 3.02-14.31, P 〈0.001). There was a significant difference between the patient subgroups with 0 or 1 and those with 2 or 3 positive markers expression statuses, and tri-marker composite index was an independent risk factor for predicting relapse in patients with intermediate-risk prostate cancer after surgery. Conclusion Composite index of c-Myc, EZH2, and p27 can be valued as powerful prognosis parameter for intermediate-risk prostate cancer patients after the surgery, and postoperative adjuvant therapy can be adopted accordingly.展开更多
Background Bladder recurrent disease is still a challenge in the treatment of upper tract urothelial carcinoma (UTUC). This controlled study aims to investigate the efficacy of early clipping of the distal ureter pr...Background Bladder recurrent disease is still a challenge in the treatment of upper tract urothelial carcinoma (UTUC). This controlled study aims to investigate the efficacy of early clipping of the distal ureter prior to nephroureterectomy (NU) to prevent bladder recurrence after UTUC.展开更多
基金This work was supported by grants from the National Natural Science Foundation of China(No.81972394 and 82272856)the Guang Dong Basic and Applied Basic Research Foundation(No.2022A1515010437)+1 种基金the President Foundation of The Third Affiliated Hospital of Southern Medical University(No.YM2021010,No.YM2021011)the Scientific and Technological Support Project of Guizhou Province(Qian Ke He Zhi Cheng 2023]Yi Ban 262)。
文摘Targeted delivery of anti-tumor drugs and overcoming drug resistance in malig-nant tumor cells remain significant clinical challenges.However,there are only few effective methods to address these issues.Extracellular vesicles(EVs),actively secreted by cells,play a crucial role in intercellular information transmis-sion and cargo transportation.Recent studies have demonstrated that engineered EVs can serve as drug delivery carriers and showed promising application prospects.Nevertheless,there is an urgent need for further improvements in the isolation and purification of EVs,surface modification techniques,drug assem-bly processes,and precise recognition of tumor cells for targeted drug delivery purposes.In this review,we summarize the applications of engineered EVs in cancer treatment and overcoming drug resistance,and current challenges asso-ciated with engineered EVs are also discussed.This review aims to provide new insights and potential directions for utilizing engineered EVs as targeted delivery systems for anti-tumor drugs and overcoming drug resistance in the near future.
基金This study was supported by the grants from the Program of 5010 of Sun Yat-sen University,the National Natural Science Foundation of China,the Key Project of Chinese Ministry of Health,Chinese National Hi-Tech Research and Development Program,the National Natural Science Foundation of China
文摘Background c-Myc, EZH2 and p27 were defined to modulate anti-tumoral effects and had ability in predicting prostate cancer value of prognosis is rarely. This study aimed to investigate the patients with intermediate-risk prostate cancer after surgery. the behavior of prostate cancer with pro-tumoral or progression, but the research of their co-expression prognostic value of combining tri-marker together in Methods Expression levels of c-Myc, EZH2 and p27 in 129 patients with intermediate-risk prostate cancer were assessed using immunohistochemistry in a semi-quantitative manner. The expression profiles of these three markers were analyzed and investigated for association with biochemical recurrence. Results In all, fifty of 129 cases experienced biochemical recurrence during a median follow-up time of 31 months (range, 6-60 months). Of these relapse patients, one case without and 10 cases with any single positive marker were observed; 39 cases were detected with any two or all three positive markers (22 cases with any two and 17 cases with all three positive markers). Survival analysis showed that patients with over-expression of c-Myc or EZH2, and lower expression of p27 manifested significantly higher biochemical recurrence rates. Subsequent multivariate analysis revealed that c-Myc, EZH2 and p27 expression statuses showed potential in predicting relapse, respectively. Notably, combining three markers together as a "composite index" (0 or 1, vs. 2 or 3 positive markers) provided powerful prognostic value (HR 6.57, 95% CI 3.02-14.31, P 〈0.001). There was a significant difference between the patient subgroups with 0 or 1 and those with 2 or 3 positive markers expression statuses, and tri-marker composite index was an independent risk factor for predicting relapse in patients with intermediate-risk prostate cancer after surgery. Conclusion Composite index of c-Myc, EZH2, and p27 can be valued as powerful prognosis parameter for intermediate-risk prostate cancer patients after the surgery, and postoperative adjuvant therapy can be adopted accordingly.
基金This study was supported by a grant from-the National Natural Science Foundation of China (No. 81072101/H1619).
文摘Background Bladder recurrent disease is still a challenge in the treatment of upper tract urothelial carcinoma (UTUC). This controlled study aims to investigate the efficacy of early clipping of the distal ureter prior to nephroureterectomy (NU) to prevent bladder recurrence after UTUC.